| Literature DB >> 32887977 |
Yanchun Peng1,2, Alexander J Mentzer3,4,5, Guihai Liu2,4,6, Xuan Yao1,2,4, Zixi Yin1,2, Danning Dong2,4,7, Wanwisa Dejnirattisai4, Timothy Rostron8, Piyada Supasa4, Chang Liu2,4, César López-Camacho3,4, Jose Slon-Campos4, Yuguang Zhao4, David I Stuart2,3,4,9, Guido C Paesen3, Jonathan M Grimes3,4,9, Alfred A Antson10, Oliver W Bayfield10, Dorothy E D P Hawkins10, De-Sheng Ker10, Beibei Wang2,4, Lance Turtle11,12, Krishanthi Subramaniam12, Paul Thomson12, Ping Zhang4, Christina Dold13,14, Jeremy Ratcliff4, Peter Simmonds4, Thushan de Silva15, Paul Sopp8, Dannielle Wellington1,2, Ushani Rajapaksa2,4, Yi-Ling Chen1, Mariolina Salio1, Giorgio Napolitani1, Wayne Paes4, Persephone Borrow4, Benedikt M Kessler2,4, Jeremy W Fry16, Nikolai F Schwabe16, Malcolm G Semple12,17, J Kenneth Baillie18, Shona C Moore12, Peter J M Openshaw19, M Azim Ansari4, Susanna Dunachie4,5, Eleanor Barnes4,5,20, John Frater4,5, Georgina Kerr4, Philip Goulder4,5, Teresa Lockett5, Robert Levin21, Yonghong Zhang2,6, Ronghua Jing6, Ling-Pei Ho1,2,4,20, Richard J Cornall1,4,5, Christopher P Conlon2,4,5, Paul Klenerman4,5,20, Gavin R Screaton4,5,20, Juthathip Mongkolsapaya2,4,20,22, Andrew McMichael2,4, Julian C Knight2,3,4,5, Graham Ogg1,2,5,20, Tao Dong23,24,25.
Abstract
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide-MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32887977 PMCID： PMC7611020 DOI： 10.1038/s41590-020-0782-6
Source DB: PubMed Journal: Nat Immunol ISSN： 1529-2908 Impact factor: 25.606